The recent years have witnessed major advances in the treatment of benign rare blood disorders such as hemophilia, sickle cell disease (SCD), and cold agglutinin disease (CAD). Moreover, new guidelines have been developed for the diagnosis and management of these blood disorders. Clinicians including hematologists and emergency department physicians need to remain up to date on the various aspects of management of these hematological disorders to diagnose, treat, and manage associated complications. Moreover, access to novel therapies remains challenging due to payer restrictions including step therapy policies. Hematologists and their care team need education on streamlining the prior authorization processes to prevent treatment delays.
The CME Outfitters, LLC Hematology Hub is designed to provide clinicians with the latest clinical practice guidelines, diagnostic strategies and tools, scientific updates on current and emerging therapies, latest guidelines to optimize the management of hematological disorders, and strategies to streamline prior authorization process. In addition, the Hematology Hub also provides patient education tools to empower patients to make informed decisions about their care and to navigate the prior authorization process.
One Size Does Not Fit All: Using Population Pharmacokinetics for Tailored Hemophilia Care
 Register Now | In order to prevent and treat bleeding in patients with hemophilia A, the activity of the replaced clotting factor VIII must reach or exceed a target level over a period of time. Pharmacokinetic (PK) measures are therefore used to determine the dosing regimen of the different factor VIII replacement products. Recently, extended half-life recombinant factor VIII products with improved PK profiles have been approved and these reduce treatment burden and improve treatment adherence. In this CME Outfitters live and on-demand webcast renowned hematologists will discuss the clinical significance of the results of the head-to-head comparison study of PK profiles of extended half life factor VIII products including the application of population PK models and shared decision-making to provide personalized hemophilia A therapy. |
Management of Hemophilia in the Emergency Department: A Case-Based Discussion
 Participate Now | This CME Outfitters LLC Snack features case-based learning designed to facilitate problem-solving and therefore bridge the gap between evidence and actionable changes in practice as they pertain to updated guidelines, new treatments, and emerging therapies that will help physicians and other professionals who work in the ED with identifying, monitoring, and managing patients with hemophilia. |
Management of Sickle Cell Disease in the Emergency Department: A Case-Based Discussion
 Participate Now | This CME Outfitters Snack is included in the 3-part series on management of benign rare blood disorders in the ED. It features a video physician-patient case scenario with hematological insights on the evaluation and management of patients in the ED and current and emerging treatments for SCD. |
Management of Cold Agglutinin Disease in the Emergency Department: A Case-Based Discussion
 Participate Now | In this CME Outfitters Snack, updated guidelines and new treatments are highlighted in a video case identifying CAD in the ED and providing appropriate management, including ensuring best practices for blood testing and blood transfusion in patients with CAD. |
Novel Therapies for Hemophilia: What Does the Evidence Show?
 Participate Now | In the first module of this CME Outfitters 3-part snack series on prior authorization for hemophilia, expert faculty discuss new and emerging therapies for hemophilia and the evidence for use in patients with hemophilia. We encourage learners to complete all 3 CME Snacks in this series to receive a Certificate of Excellence in Prior Authorization. |
Improving Access to Hemophilia Therapies
 Participate Now | The second module in this CME Outfitters Snack series on prior authorization for hemophilia features expert faculty reviewing provider and payer insights into best practices for streamlining the prior authorization process to improve patient access to hemophilia therapies. |
Putting Shared Decision-Making into Practice in Hemophilia Care
 Participate Now | In this third module of the three-part CME Outfitters Snack series on prior authorization for hemophilia concludes with a focus on developing team-based approaches for integrating SDM and patient education into practice for patients with hemophilia. |
Hemophilia
- Guidelines For The Management Of Hemophillia 2nd edition
- Guidelines For Emergency Department Management Of Individuals With Hemophillia And Other Bleeding Disorders
- NHF Position Statement Regarding Standardized Prior Authorization
- HFA Prior Authorization Issue Brief
- HFA Issue Brief: Non-Medical Switching and Step Therapy
Hemophilia
- What is hemophilia A?
- What is hemophilia B?
- Treatment of hemophilia
- Types of prophylaxis
- What is an inhibitor?
- Who is at risk for developing an inhibitor?
- Treatment for inhibitors
- What types of bleeds are there?
- Preventing bleeding
- Costs and considerations
- Video: Prior Authorization in Hemophilia
Sickle Cell Disease
Cold Agglutinin Disease